Merskey HBugduk N. Classification of Chronic Pain. Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms2nd Ed. IASP PressSeattle, WA. 1994.
- Export Citation
)| false . , Merskey H Bugduk N Classification of Chronic Pain. Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, 2nd Ed. IASP Press, Seattle, WA. 1994.
van den Beuken-van Everdingen MHde Rijke JMKessels AG. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437–1449.
Te Boveldt NVernooij-Dassen MBurger N. Pain and its interference with daily activities in medical oncology outpatients. Pain Physician 2013;16:379–389.
Temel JSGreer JAMuzikansky A. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733–742.
Zimmermann CSwami NKrzyzanowska M. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014;383:1721–1730.
Grudzen CRRichardson LDJohnson PN. Emergency department-initiated palliative care in advanced cancer: a randomized clinical trial. JAMA Oncol 2016;2:591–598.
Bakitas MATosteson TDLi Z. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 2015;33:1438–1445.
Bakitas MLyons KDHegel MT. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009;302:741–749.
Greco MTRoberto ACorli O. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol 2014;32:4149–4154.
Martin LAHagen NA. Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. J Pain Symptom Manage 1997;14:99–117.
Stjernswärd JColleau SMVentafridda V. The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. J Pain Symptom Manage 1996;12:65–72.
U.S. Food and Drug Administration. Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Stratgey (REMS). Silver Spring MD: 2014. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM289730.pdf. Accessed March 7 2019.
U.S. Food and Drug Administration. Extended-Release (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS). Silver Spring MD: 2015. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf. Accessed March 7 2019.
Syrjala KLAbrams JRPolissar NL. Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain 2008;135:175–186.
Mercadante SLBerchovich MCasuccio A. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 2007;24:13–19.
Stockler MVardy JPillai A. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004;22:3389–3394.
American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331–1346.
Israel FJParker GCharles M. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2010;39:548–554.
U.S. Food and Drug Administration. FDA Drug Safety Communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. 2011. Available at: http://www.fda.gov/drugs/drugsafety/ucm239821.htm. Accessed March 7, 2019.
U.S. Food and Drug Administration. Information for Healthcare Professionals: concomitant use of ibuprofen and aspirin. 2006. Available at: https://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm161282.pdf. Accessed March 7 2019.
Tielemans MMEikendal TJansen JB. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 2010;33:443–453.
Laine LCurtis SPCryer B. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther 2010;32:1240–1248.
U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. Available at: https://www.fda.gov/drugs/drugsafety/ucm451800. Accessed April 12 2019.
Bally MDendukuri NRich B. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909.
Jongen JLHuijsman MLJessurun J. The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. J Pain Symptom Manage 2013;46:581–590 e581.
Jin YDesta ZStearns V. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30–39.
Haque RShi JSchottinger JE. Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst 2016;108:(3)
Azoulay LDell’Aniello SHuiart L. Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 2011;126:695–703.
Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22:27–47.
Baron RBrunnmüller UBrasser M. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. Eur J Pain 2008;12:850–858.
Chen DLLi YHWang ZJ. The research on long-term clinical effects and patients’ satisfaction of gabapentin combined with oxycontin in treatment of severe cancer pain. Medicine (Baltimore) 2016;95:e5144.
Dou ZJiang ZZhong J. Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy. Asia Pac J Clin Oncol 2017;13:e57–e64.
Bar Ad VWeinstein GDutta PR. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer 2010;116:4206–4213.
Raptis EVadalouca AStavropoulou E. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Pain Pract 2014;14:32–42.
Donovan KAChang YDOberoi-Jassal R. Relationship of cannabis use to patient-reported symptoms in cancer patients seeking supportive/palliative care [published online February 22, 2019]. J Palliat Med. doi: 10.1089/jpm.2018.0533
Steele GArneson TZylla D. A comprehensive review of cannabis in patients with cancer: availability in the USA, general efficacy, and safety. Curr Oncol Rep 2019;21:10.
National Center for Complementary and Integrative Health. Marijuana and Cannabinoids. 2019. Available at: https://nccih.nih.gov/health/marijuana. Accessed April 25 2019.
Drugs of Abuse: a DEA Resource Guide; 2017. Available at: https://www.dea.gov/sites/default/files/sites/getsmartaboutdrugs.com/files/publications/DoA_2017Ed_Updated_6.16.17.pdf.
Pergam SAWoodfield MCLee CM. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 2017;123:4488–4497.
Tringale KRHuynh-Le MPSalans M. The role of cancer in marijuana and prescription opioid use in the United States: A population-based analysis from 2005 to 2014. Cancer 2019;125:2242–2251.
Johnson JRBurnell-Nugent MLossignol D. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010;39:167–179.
- Search Google Scholar
- Export Citation
)| false . , Johnson JR , Burnell-Nugent M , Lossignol D Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. 2010; 39: 167– 179.
Portenoy RKGanae-Motan EDAllende S. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 2012;13:438–449.
Lynch MECesar-Rittenberg PHohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 2014;47:166–173.
Monte AAShelton SKMills E. Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med 2019;170:531–537.
Cherny NI. The pharmacologic management of cancer pain. Oncology (Williston Park) 2004;18:1499–1515. discussion 1516 1520–1521. 1522 1524.
Bandieri ERomero MRipamonti CI.Early Strong Opioid Treatment Study (ESOT) Investigators. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 2016;34:436–442.
Andersen GJensen NHChristrup L. Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliat Med 2002;16:107–114.
Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000;27:524–528.
Sande TALaird BJFallon MT. The use of opioids in cancer patients with renal impairment-a systematic review. Support Care Cancer 2017;25:661–675.
Klepstad PKaasa SBorchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 2000;55:713–719.
Klepstad PKaasa SSkauge M. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand 2000;44:656–664.
Tiseo PJThaler HTLapin J. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995;61:47–54.
Portenoy RKFoley KMStulman J. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991;47:13–19.
Mercadante SVellucci RCuomo A. Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Support Care Cancer 2015;23:1349–1354.
Caraceni AHanks GKaasa S.European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58–e68.
Wang DDMa TTZhu HD. Transdermal fentanyl for cancer pain: trial sequential analysis of 3406 patients from 35 randomized controlled trials. J Cancer Res Ther 2018; 14(8 Supplement)14–21.
Kornick CASantiago-Palma JKhojainova N. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer 2001;92:3056–3061.
Portenoy RKTaylor DMessina J. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805–811.
Weinstein SMMessina JXie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. Cancer 2009;115:2571–2579.
Srinivasan VWielbo DTebbett IR. Analgesic effects of codeine-6-glucuronide after intravenous administration. Eur J Pain 1997;1:185–190.
Kirchheiner JSchmidt HTzvetkov M. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:257–265.
Wright AWMather LESmith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69:409–420.
Han HSLee KHLee KH. A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics. Support Care Cancer 2014;22:741–750.
Yu SShen WYu L. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. J Pain 2014;15:835–844.
- Search Google Scholar
- Export Citation
)| false . , Yu S , Shen W , Yu L Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. 2014; 15: 835– 844.
Inoue SSaito YTsuneto S. A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Jpn J Clin Oncol 2018;48:542–547.
- Search Google Scholar
- Export Citation
)| false . , Inoue S , Saito Y , Tsuneto S A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. 2018; 48: 542– 547.
Davis MPVarga JDickerson D. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 2003;11:84–92.
Ordóñez Gallego AGonzález Barón MEspinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol 2007;9:298–307.
Gabrail NYDvergsten CAhdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 2004;20:911–918.
Schmidt-Hansen MBennett MIArnold S. Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review. BMJ Support Palliat Care 2018;8:117–128.
Ahmedzai SHNauck FBar-Sela G. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50–60.
- Search Google Scholar
- Export Citation
)| false . , Ahmedzai SH , Nauck F , Bar-Sela G A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. 2012; 26: 50– 60.
Ahmedzai SHLeppert WJanecki M. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer 2015;23:823–830.
McPherson MLWalker KADavis MP. Safe and appropriate use of methadone in hospice and palliative care: expert consensus white paper. J Pain Symptom Manage 2019;57:635–645.
Parsons HAde la Cruz MEl Osta B. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010;116:520–528.
Fürst PLundström SKlepstad P. Improved pain control in terminally ill cancer patients by introducing low-dose oral methadone in addition to ongoing opioid treatment. J Palliat Med 2018;21:177–181.
Krantz MJKutinsky IBRobertson AD. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802–805.
Kornick CAKilborn MJSantiago-Palma J. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499–506.
Reddy SHui DEl Osta B. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med 2010;13:33–38.
Chou RCruciani RAFiellin DA.Heart Rhythm Society. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain 2014;15:321–337.
Atkinson TJFudin JPandula A. Medication pain management in the elderly: unique and underutilized analgesic treatment options. Clin Ther 2013;35:1669–1689.
Rowbotham MCTwilling LDavies PS. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223–1232.
Grond SRadbruch LMeuser T. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 1999;18:174–179.
Rodriguez RFBravo LECastro F. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med 2007;10:56–60.
Wiffen PJDerry SMoore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev 2017;5:CD012508.
Afilalo MEtropolski MSKuperwasser B. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30:489–505.
- Search Google Scholar
- Export Citation
)| false . , Afilalo M , Etropolski MS , Kuperwasser B Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. 2010; 30: 489– 505.
Buynak RShapiro DYOkamoto A. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010;11:1787–1804.
Schwartz SEtropolski MShapiro DY. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011;27:151–162.
Mercadante SPorzio GFerrera P. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 2012;28:1775–1779.
Mercadante SPorzio GAdile C. Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. Curr Med Res Opin 2014;30:2063–2068.
Naing CAung KRacloz V. Safety and efficacy of transdermal buprenorphine for the relief of cancer pain. J Cancer Res Clin Oncol 2013;139:1963–1970.
Pergolizzi JVJr. Mercadante SEchaburu AV.Euromed Communications meeting. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009;25:1517–1528.
Deandrea SCorli OMoschetti I. Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review. Ther Clin Risk Manag 2009;5:707–718.
Melilli GSamolsky Dekel BGFrenquelli C. Transdermal opioids for cancer pain control in patients with renal impairment. J Opioid Manag 2014;10:85–93.
Lundorff LSjøgren PHansen OB. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study. J Opioid Manag 2013;9:255–262.
Hardy JQuinn SFazekas B. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012;30:3611–3617.
Bredlau ALThakur RKorones DN. Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Med 2013;14:1505–1517.
DeWilde KELevitch CFMurrough JW. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci 2015;1345:47–58.
Fond GLoundou ARabu C. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 2014;231:3663–3676.
Lee EEDella Selva MPLiu A. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry 2015;37:178–184.
Sharma SRajagopal MRPalat G. A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage 2009;37:85–93.
Jendoubi ANaceur IBBouzouita A. A comparison between intravenous lidocaine and ketamine on acute and chronic pain after open nephrectomy: A prospective, double-blind, randomized, placebo-controlled study. Saudi J Anaesth 2017;11:177–184.
Ferrini RPaice JA. How to initiate and monitor infusional lidocaine for severe and/or neuropathic pain. J Support Oncol 2004;2:90–94.
Carroll I. Intravenous lidocaine for neuropathic pain: diagnostic utility and therapeutic efficacy. Curr Pain Headache Rep 2007;11:20–24.
Nijland LSchmidt PFrosch M. Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review. Support Care Cancer 2019;27:33–42.
Davies ABuchanan AZeppetella G. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 2013;46:619–628.
Jandhyala RFullarton JRBennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage 2013;46:573–580.
Zeppetella GDavies AEijgelshoven IJansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage 2014;47:772–785.
VA/DoD clinical practice guideline for opioid therapy for chronic pain. Version 3.0. 2017. Available at: https://www.healthquality.va.gov/guidelines/Pain/cot/VADoDOTCPG022717.pdf. Accessed March 7, 2019.
Meltzer ECRybin DSaitz R. Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain 2011;152:397–402.
Anghelescu DLEhrentraut JHFaughnan LG. Opioid misuse and abuse: risk assessment and management in patients with cancer pain. J Natl Compr Canc Netw 2013;11:1023–1031.
McNicol EHorowicz-Mehler NFisk RA.Americal Pain Society. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231–256.
Moryl NCarver AFoley KM. Pain and palliation. In: Holland JF Frei E eds. Cancer Medicine. Vol. I7th ed. Hamilton ON: BC Decker Inc; 2006:1113-1124.
Moryl NObbens EAOzigbo OH. Analgesic effect of gefitinib in the treatment of non-small cell lung cancer. J Support Oncol 2006;4:111.
Rajagopal AVassilopoulou-Sellin RPalmer JL. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004;100:851–858.
Boettger SBreitbart W. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care 2005;3:227–237.
Breitbart WMarotta RPlatt MM. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231–237.
Bruera EBelzile MNeumann C. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 2000;19:427–435.
Marinella MA. Acute colonic pseudo-obstruction complicated by cecal perforation in a patient with Parkinson’s disease. South Med J 1997;90:1023–1026.
Tarcatu DTamasdan CMoryl N. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag 2007;3:167–170.
Hawley PHByeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med 2008;11:575–581.
Tarumi YWilson MPSzafran O. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage 2013;45:2–13.
Rauck RSlatkin NEStambler N. Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Pract 2017;17:820–828.
Michna EBlonsky ERSchulman S. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain 2011;12:554–562.
Portenoy RKThomas JMoehl Boatwright ML. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008;35:458–468.
Sanz Rubiales Adel Valle Rivero ML. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;359:1070–1071.
Thomas JKarver SCooney GA. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332–2343.
Chey WDWebster LSostek M. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014;370:2387–2396.
Katakami NHarada TMurata T. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol 2017;35:3859–3866.
Nee JZakari MSugarman MA. Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:1569–1584.
Cryer BKatz SVallejo R. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2014;15:1825–1834.
Jamal MMAdams ABJansen JP. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol 2015;110:725–732.
Chang LLembo AJLavins BJ. The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials. Aliment Pharmacol Ther 2014;40:1302–1312.
- Search Google Scholar
- Export Citation
)| false . , Chang L , Lembo AJ , Lavins BJ The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials. 2014; 40: 1302– 1312.
Kaneishi KKawabata MMorita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manage 2012;44:604–607.
Navari RMNagy CKGray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013;21:1655–1663.
Bruera ESeifert LWatanabe S. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage 1996;11:147–153.
Herman TSEinhorn LHJones SE. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979;300:1295–1297.
Steele NGralla RJBraun DW Jr. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980;64:219–224.
Sallan SECronin CZelen M. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980;302:135–138.
Sallan SEZinberg NEFrei E III. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975;293:795–797.
Gagnon PAllard PMâsse B. Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage 2000;19:412–426.
Agar MRLawlor PGQuinn S. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med 2017;177:34–42.
Hui DFrisbee-Hume SWilson A. Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial. JAMA 2017;318:1047–1056.
Bruera EMacmillan KHanson J. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13–16.
U.S. Food and Drug Administration. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. 2016. Available at: https://www.fda.gov/downloads/drugs/drugsafety/ucm518672.pdf. Accessed March 7 2019.
Prescribing information. NARCAN® (naloxone hydrochloride) nasal spray. 2017. Available at: https://www.narcan.com/pdf/NARCAN-Prescribing-Information.pdf. Accessed March 7 2019.
Coffin POBehar ERowe C. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med 2016;165:245–252.
Reddy AYennurajalingam SDesai H. The opioid rotation ratio of hydrocodone to strong opioids in cancer patients. Oncologist 2014;19:1186–1193.
Reddy ATayjasanant SHaider A. The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients. Cancer 2016;122:149–156.
Reddy AYennurajalingam SReddy S. The opioid rotation ratio from transdermal fentanyl to “strong” opioids in patients with cancer pain. J Pain Symptom Manage 2016;51:1040–1045.
McLean STwomey F. Methods of rotation from another strong opioid to methadone for the management of cancer pain: a systematic review of the available evidence. J Pain Symptom Manage 2015;50:248–259.
Scholl LSeth PKariisa M. Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep 2018;67:1419–1427.
U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS) for opioid analgesics. 2017. Available at: https://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm. Accessed December 1 2017.
FDA takes important steps to encourage appropriate and rational prescribing of opioids through final approval of new safety measures governing the use of immediate-release opioid analgesic medications; 2018. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620935.htm.
FDA Education Blueprint for health care providers involved in the treatment and monitoring of patients with pain. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/rems/Opioid_analgesic_2018_09_18_FDA_Blueprint.pdf.
U.S. Food and Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS). Available at: http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm. Accessed January 28 2019.
Barclay JSOwens JEBlackhall LJ. Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen. Support Care Cancer 2014;22:1883–1888.
Caraceni AZecca EBonezzi C. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004;22:2909–2917.
Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med 2011;25:553–559.
Kane CMMulvey MRWright S. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis. Palliat Med 2018;32:276–286.
Fleming JAO’Connor BD. Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag 2009;14:381–388.
Gammaitoni ARAlvarez NAGaler BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43:111–117.
Garzón-Rodríguez CCasals Merchan MCalsina-Berna A. Lidocaine 5 % patches as an effective short-term co-analgesic in cancer pain. Preliminary results. Support Care Cancer 2013;21:3153–3158.
Liu ZXu YLiu ZL. Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. Int J Clin Oncol 2017;22:980–985.
Sima LFang WXWu XM. Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial. J Clin Pharm Ther 2012;37:27–31.
Chow EMeyer RMDing K. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol 2015;16:1463–1472.
Body JJDiel IJLichinitzer M. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133–1137.
Body JJDiel IJBell R. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306–312.
Cleeland CSBody JJStopeck A. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013;119:832–838.
Rosen LSGordon DKaminski M. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377–387.
Wardley ADavidson NBarrett-Lee P. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005;92:1869–1876.
- Search Google Scholar
- Export Citation
)| false . , Wardley A , Davidson N , Barrett-Lee P Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. 2005; 92: 1869– 1876.
Vadhan-Raj Svon Moos RFallowfield LJ. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 2012;23:3045–3051.
Martin MBell RBourgeois H. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 2012;18:4841–4849.
Van Poznak CSomerfield MRBarlow WE. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. J Clin Oncol 2017;35:3978–3986.
Malviya AGerrand C. Evidence for orthopaedic surgery in the treatment of metastatic bone disease of the extremities: a review article. Palliat Med 2012;26:788–796.
Dupuy DELiu DHartfeil D. Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial. Cancer 2010;116:989–997.
Lutz SBerk LChang E.American Society for Radiation Oncology (ASTRO). Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965–976.
Goetz MPCallstrom MRCharboneau JW. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 2004;22:300–306.
Kashima MYamakado KTakaki H. Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma. AJR Am J Roentgenol 2010;194:536–541.
Li CZhang WFan W. Noninvasive treatment of malignant bone tumors using high-intensity focused ultrasound. Cancer 2010;116:3934–3942.
Napoli AAnzidei MMarincola BC. Primary pain palliation and local tumor control in bone metastases treated with magnetic resonance-guided focused ultrasound. Invest Radiol 2013;48:351–358.
Liberman BGianfelice DInbar Y. Pain palliation in patients with bone metastases using MR-guided focused ultrasound surgery: a multicenter study. Ann Surg Oncol 2009;16:140–146.
Silver JKGilchrist LS. Cancer rehabilitation with a focus on evidence-based outpatient physical and occupational therapy interventions. Am J Phys Med Rehabil 2011; 90(5 Suppl 1)S5–S15.
Silver JKBaima JMayer RS. Impairment-driven cancer rehabilitation: an essential component of quality care and survivorship. CA Cancer J Clin 2013;63:295–317.
Jones LFitzgerald GLeurent B. Rehabilitation in advanced, progressive, recurrent cancer: a randomized controlled trial. J Pain Symptom Manage 2013;46:315–325.
Eilers JHarris DHenry K. Evidence-based interventions for cancer treatment-related mucositis: putting evidence into practice. Clin J Oncol Nurs 2014; 18(Suppl)80–96.
Riley PGlenny AMWorthington HV. Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev 2015; (12):CD011552.
Idayu Mat Nawi RLei Chui PWan Ishak WZ. Oral cryotherapy: prevention of oral mucositis and pain among patients with colorectal cancer undergoing chemotherapy. Clin J Oncol Nurs 2018;22:555–560.
Kataoka TKiyota NShimada T. Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. Auris Nasus Larynx 2016;43:677–684.
McGuire DBFulton JSPark J.Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 2013;21:3165–3177.
- Search Google Scholar
- Export Citation
)| false . , McGuire DB , Fulton JS , Park J Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of basic oral care for the management of oral mucositis in cancer patients. 2013; 21: 3165– 3177.
Kwong KK. Prevention and treatment of oropharyngeal mucositis following cancer therapy: are there new approaches? Cancer Nurs 2004;27:183–205.
Shih AMiaskowski CDodd MJ. A research review of the current treatments for radiation-induced oral mucositis in patients with head and neck cancer. Oncol Nurs Forum 2002;29:1063–1080.
Chitapanarux ITungkasamit TPetsuksiri J. Randomized control trial of benzydamine HCl versus sodium bicarbonate for prophylaxis of concurrent chemoradiation-induced oral mucositis. Support Care Cancer 2018;26:879–886.
Epstein JBSilverman SJr. Paggiarino DA. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 2001;92:875–885.
Clark KLam LCurrow D. Reducing gastric secretions--a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction? Support Care Cancer 2009;17:1463–1468.
Deng GERausch SMJones LW. Complementary therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e420S–e436S.
Greenlee HDuPont-Reyes MJBalneaves LG. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 2017;67:194–232.
Lyman GHGreenlee HBohlke K. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO Clinical Practice Guideline. J Clin Oncol 2018;36:2647–2655.
Chiu HYHsieh YJTsai PS. Systematic review and meta-analysis of acupuncture to reduce cancer-related pain. Eur J Cancer Care (Engl) 2017;26:e12457.
Hershman DLUnger JMGreenlee H. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial. JAMA 2018;320:167–176.
Pfister DGCassileth BRDeng GE. Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol 2010;28:2565–2570.
Raphael JHester JAhmedzai S. Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med 2010;11:872–896.
- Search Google Scholar
- Export Citation
)| false . , Raphael J , Hester J , Ahmedzai S Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. 2010; 11: 872– 896.
Stoelb BLMolton IRJensen MP. The efficacy of hypnotic analgesia in adults: a review of the literature. Contemp Hypn 2009;26:24–39.
Huang STGood MZauszniewski JA. The effectiveness of music in relieving pain in cancer patients: a randomized controlled trial. Int J Nurs Stud 2010;47:1354–1362.
Kwekkeboom KLCherwin CHLee JW. Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. J Pain Symptom Manage 2010;39:126–138.
Cassileth BRKeefe FJ. Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain. Oncologist 2010;15(Suppl 2):19–23.
Montgomery GHWeltz CRSeltz M. Brief presurgery hypnosis reduces distress and pain in excisional breast biopsy patients. Int J Clin Exp Hypn 2002;50:17–32.
Bennett MIBagnall AMJosé Closs S. How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis. Pain 2009;143:192–199.
Keefe FJAbernethy APC Campbell L. Psychological approaches to understanding and treating disease-related pain. Annu Rev Psychol 2005;56:601–630.
Sheinfeld Gorin SKrebs PBadr H. Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol 2012;30:539–547.
Puchalski CFerrell BVirani R. Improving the quality of spiritual care as a dimension of palliative care: the report of the Consensus Conference. J Palliat Med 2009;12:885–904.
Eidelman AWhite TSwarm RA. Interventional therapies for cancer pain management: important adjuvants to systemic analgesics. J Natl Compr Canc Netw 2007;5:753–760.
Wong GYSchroeder DRCarns PE. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004;291:1092–1099.
Cheville ALBasford JR. Role of rehabilitation medicine and physical agents in the treatment of cancer-associated pain. J Clin Oncol 2014;32:1691–1702.
Arcidiacono PGCalori GCarrara S. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011; (3):CD007519.
Zhang CLZhang TJGuo YN. Effect of neurolytic celiac plexus block guided by computerized tomography on pancreatic cancer pain. Dig Dis Sci 2008;53:856–860.
Zheng SHe LYang X. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: a prospective cohort study. Medicine (Baltimore) 2017;96:e6354.
- Search Google Scholar
)| false . , Zheng S , He L , Yang X Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: a prospective cohort study. 2017; 96: e6354.